Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News PolyPid Ltd PYPD

Healthcare Biotechnology
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing... see more

Current News (NDAQ:PYPD)

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

GlobeNewswire 9 days ago

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

GlobeNewswire March 31, 2026

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

GlobeNewswire March 17, 2026

PolyPid Announces Participation in Upcoming Investor Conferences

GlobeNewswire February 25, 2026

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

GlobeNewswire February 11, 2026

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

GlobeNewswire January 28, 2026

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

GlobeNewswire December 16, 2025

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

GlobeNewswire December 3, 2025

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

GlobeNewswire November 25, 2025
View More News ››

Opinion & Analysis (NDAQ:PYPD)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:PYPD)

Buy buddy buy because it's taking off this morning.

This stock is signalling a big upswing for shareholders today anyway
coolfooldumbguy - June 9, 2025

PYPD .... Ka F'ing Booom !!!!!

Yeeeha !!!!!!!!!!!!!!!
Iseneschal - September 12, 2022

PYPD ..... How am I doing today there Mr. Stockhouse

LMFAO PYPD ..... Cha F'ing Ching  Cheers !
Iseneschal - September 12, 2022

PYPD ....heads up....Watch list

Heading into the gap  Cheers !
Iseneschal - September 12, 2022
View more Bullboard ››

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »

Podcasts